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Is smoking a risk factor  
for metabolic syndrome?
Czy palenie tytoniu jest czynnikiem ryzyka zespołu metabolicznego?
ABSTRACT
Background. We define metabolic syndrome as a non-
-random collective incidence of glucose metabolism 
disorders related to insulin resistance, central obesity, 
dyslipidemia, arterial hypertension and other factors 
which contribute to increased risk of ischemic heart 
disease and diabetes mellitus type 2. Smoking is one 
of the most significant risk factors for ischemic heart 
disease. 
Objectives and methods. A prospective analysis of 
125 patients (75 men and 50 women) with the average 
age of 57.3 years. A subset of smokers was composed 
of 59 patients; the average number of cigarettes smo-
ked per day was 18 pieces. A subset of non-smokers 
was composed of 66 patients. We examined the pre-
sence of metabolic syndrome components according 
to the International Diabetic Federation criteria for 
the European population throughout the whole set 
of patients.
Results. Percentually higher incidence of metabolic 
syndrome occurred in the group of non-smokers. The 
incidence of metabolic syndrome in the group of smo-
kers was significantly influenced by their age. Arterial 
hypertension and impaired fasting glucose were the 
most frequent components of metabolic syndrome in 
the subset of smokers with metabolic syndrome. In 
the subset of non-smokers with metabolic syndrome 
arterial hypertension was the most frequently found 
component. 
Conclusion. The results of the research did not show 
statistically significantly increased or decreased inci-
dence of metabolic syndrome in case of smokers. We 
did not find any relation between the number of 
cigarettes smoked per day and metabolic syndrome 
development. (Diabet. Klin. 2014; 3, 4: 136–143)
Key words: metabolic syndrome, smoking, nicotine, 
obesity, cardiovascular risk
STRESZCZENIE
Wstęp. Zespół metaboliczny określa się jako współwy-
stępowanie zaburzeń metabolizmu węglowodanów 
związanych z insulinoopornością, otyłością brzuszną, 
dyslipidemią, nadciśnieniem tętniczym i innymi czyn-
nikami przyczyniającymi się do zwiększonego ryzyka 
choroby niedokrwiennej serca i cukrzycy typu 2. Jed-
nym z najważniejszych czynników ryzyka choroby 
niedokrwiennej serca jest palenie tytoniu.
Cel badania i metody. Przeprowadzono prospektyw-
ną analizę 125 chorych (75 mężczyzn i 50 kobiet), 
których średnia wieku wynosiła 57,3 roku. Podgrupa 
osób palących obejmowała 59 chorych; średnia liczba 
wypalanych dziennie papierosów wynosiła 18 sztuk. 
Podgrupa osób niepalących składała się z 66 chorych. 
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Autorzy zbadali częstość występowania zespołu me-
tabolicznego rozpoznawanego zgodnie z kryteriami 
International Diabetic Federation dla populacji euro-
pejskiej w całej badanej grupie pacjentów.
Wyniki. Większy odsetek osób z zespołem metabo-
licznym stwierdzono w grupie osób niepalących. 
Na częstość występowania zespołu metabolicznego 
w grupie osób palących istotnie wpływał wiek cho-
rych. Nadciśnienie tętnicze i nieprawidłowa glikemia 
na czczo były najczęstszymi elementami składowymi 
zespołu metabolicznego w podgrupie osób palą-
cych z zespołem metabolicznym. W podgrupie osób 
niepalących z zespołem metabolicznym najczęściej 
stwierdzanym elementem zespołu metabolicznego 
było nadciśnienie tętnicze.
Wnioski. Wyniki badania nie wykazały statystycznie 
istotnego zwiększenia ani zmniejszenia częstości 
występowania zespołu metabolicznego w przypadku 
osób palących. Autorzy nie stwierdzili żadnych zależ-
ności między liczbą wypalanych dziennie papierosów 
a rozwojem zespołu metabolicznego. (Diabet. Klin. 
2014; 3, 4: 136–143)
Słowa kluczowe: zespół metaboliczny,  
palenie tytoniu, nikotyna, otyłość, ryzyko  
sercowo-naczyniowe
Introduction, definition and diagnosis
The existence of several definitions led to problems 
with metabolic syndrome (MS) definition, especially in 
case of epidemiologic studies. In 2005 International 
Diabetic Federation (IDF) proposed a unification of this 
issue (for the clinical and laboratory personnel as well) [1]. 
The content of the definition is shown in Table 1. IDF 
has published other additional metabolic criteria for 
selected research purposes this year. These criteria are 
shown in Table 2. Metabolic syndrome is a predictor of 
ischemic heart disease (IHD). It predicts about 25% of 
new-onset ischemic heart disease [2]. A ten-year risk 
in case of men with metabolic syndrome is generally 
between 10–20%. Metabolic syndrome is a predictor 
of diabetes mellitus (DM) development. Almost half 
of the additional risk of DM was likely caused by the 
presence of metabolic syndrome [3]. Diabetes mel-
litus is a predictor of ischemic heart disease [4]. Every 
component of MS increases the cardiovascular risk. If 
more components are present, they multiply the risk. 
MS is associated with ca 3.5-fold increase in the rela-
tive risk of cardiovascular mortality [5, 6]. Smoking is 
one of the most influenceable risk factors for ischemic 
heart disease and also it is one of the most significant 
causes of death [7]. The main causes of death in case 
of smokers are, besides cardiovascular diseases, chronic 
obstructive pulmonary disease and lung cancer [8]. Pas-
sive smoking also increases the risk of coronary death 
by 22% in case of non-smokers. It decreases the level of 
HDL cholesterol by 0.1–0.15 mmol/L (by change in the 
activity of lecithin-cholesterol acyltransferase and in-
creasing the risk of vasospasm); it negatively influences 
coronary flow and increases the prevalence of diabetes 
mellitus type 2 [9, 10]. In addition to this, smoking 
also increases the level of fibrinogen and thrombocyte 
aggregability. A smoker-diabetic is in higher risk of 
cardiovascular diseases than a non-smoker diabetic, 
and even in much higher risk in comparison to a non- 
-diabetic non-smoker. The risk of cardiovascular system 
damage is increased and, similarly, the overall length 
of life is reduced by 12–15 years. During smoking, 
the levels of glycemia, insulin (hyperinsulinemia), and 
blood pressure (BP) are rapidly rising. Chronic smoking 
damages the artery endothelium and leads to insulin 
resistance. In case of smokers, hyperglycemia is mostly 
permanent and is responsible for the development of 
diabetic complications. Heavy metals in a cigarette 
— especially cadmium — also increase the incidence 
of diabetes mellitus. Observations had proven that 
the incidence of DM is significantly higher in smokers 
Table 1. Metabolic syndrome (IDF, 2005) [43]
Central obesity (waist circumference) European populations: in men > 94 cm, in women > 80 cm
Asian and Chinese populations: in men > 90 cm, in women > 80 cm
Japanese populations: in men > 90 cm, in women > 80 cm
Plus at least two of: Triglycerides > 1.7 mM/L (150 mg/dL)  
HDL-cholesterol in men < 1.04 mM/l (40 mg/dL), in women < 1.29 mM/L (50 mg/dL)
 Blood pressure:
systolic > 130 mm Hg or
diastolic > 85 mm Hg or
on antihypertensive therapy
Fasting glycemia > 5.6 mmol/L (100 mg/dL) or pre-existing diabetes mellitus
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and the risk definitely increases with the number of 
cigarettes smoked per day and is highest for those, 
who smoke 20 or more cigarettes per day. Smoking 
causes increased cholesterol concentration in blood, 
which enhances the progression of atherosclerosis in 
diabetics; the level of fibrinogen and thrombocyte ag-
gregability is also increased [11].
Methods
The examined set of patients was composed of 
125 patients (75 men and 50 women) who were pro-
spectively monitored for a 5 year period (2006–2011). 
We searched for the presence of metabolic syndrome 
components according to the IDF criteria for European 
population throughout the whole set. The set was 
composed of 59 smokers (47.2%) and 66 non-smokers 
(52.8%). The overall average age was 57.3 years, the 
average age of the smokers was 56.1 years, and in case 
of non-smokers it was 58.4 years. In the whole set there 
were 69 patients, who fulfilled the MS criteria, 33 men 
(44% of all men) and 36 women (72% of all women). 
The subset of smokers was composed of 59 patients; 
the average number of cigarettes smoked per day was 
18 pieces (pcs). Only active smokers were classified for 
the subset of smokers. A subset of non-smokers was 
composed of 66 patients. Ex-smokers, who ceased smok-
ing more than 20 years ago, were included in the subset 
of non-smokers as well. After processing the data, the 
groups of men and women were evaluated separately. 
We used Student’s t-test. A null hypothesis used in this 
test was the claim that there are no statistically signifi-
cant between-group differences in the mean values of 
analyzed parameters. As the alternative hypothesis we 
used the claim that the mean of waist circumference in 
smokers is smaller than the mean of waist circumference 
in non-smokers. We determined the Pearson’s correlation 
coefficient for finding out the correlation of the number of 
cigarettes smoked per day and the number of individual 
components of the MS. Further, we used the chi-square 
test for finding out the independence from age regarding 
MS incidence in smokers and non-smokers.
Results
The set contained 69 patients who fulfilled the IDF 
criteria for MS. Those were 33 men (44% of all men) and 
36 women (72% of all women). In the subset of smokers 
there were 40.7% of patients, who fulfilled the criteria 
for MS, and in the subset of non-smokers there were 
68.2% of such patients. Higher incidence of MS in the 
group of non-smokers is related to the smaller waist cir-
cumference in the group of smokers, as well as lower in-
cidence of arterial hypertension (AH) in smokers (Tab. 3). 
The incidence of MS in smokers was statistically signifi-
cantly dependent on their age, whilst the incidence of 
MS in non-smokers was not statistically significantly 
dependent on their age. Arterial hypertension and 
Table 2. Additional metabolic criteria for research (IDF, 2005) [29, 44]
Abnormal fat distribution Overall fat distribution (DXA)
 Central fat distribution (CT/ MRI)
 Biomarkers of fat tissue: leptin, adiponectin
Fat content in liver (MRS)
Atherogenic dyslipidemia (additionally to triglycerides  
and low HDL-cholesterol)
Dysglycemia insulin resistance (additionally to increased fasting 
glycemia) 
 
 
 
 
Vascular dysregulation (additionally to blood pressure increase)
 
Proinflammatory state
 
ApoB (or non-HDL-cholesterol)
Small dense LDL particles
oGGT
Fasting insulinemia/levels of proinsulin
HOMA-IR
IR by Bergman’s minimal model
Increase of free fatty acids (fasting and during oGTT) 
M value from clamp
Measuring endothelium dysfunction
Microalbuminuria
Increase in CRP (SAA)
Increase in inflammatory cytokines (TNF-a, IL-6)
Decrease in adiponectin values 
Table 3. Average waist circumference
Average waist  
circumference [cm]
Average waist  
circumference [cm]
Male smokers 95.4 100.6
Female smokers 92.2 95.5
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impaired fasting glucose of comparable incidence were 
the most frequent components of MS in the subset of 
smokers with MS. Arterial hypertension was most fre-
quent component in the subset of non-smokers. In the 
whole set of patients (without respect to MS) impaired 
fasting glucose occurred most frequently in smokers, 
whilst abdominal obesity occurred most frequently 
in non-smokers. The distribution of the incidence of 
single MS components in smokers and non-smokers 
is shown in Figure 1. Average waist circumference 
in the examined set was 98 cm. Male smokers had 
5.2 cm smaller average waist circumference than male 
non-smokers. In case of women the average differ-
ence in waist circumference was 3.3 cm. There were 
65.6% of patients with AH in the examined set. In the 
subset of smokers it was 62.7% and in the subset of 
non-smokers it was 68.2%. Lower values of blood pres-
sure (BP) are related to lower weight and are probably 
connected with vasodilatative effect of cotinine — the 
main metabolite of nicotine. We showed a statistically 
significant dependence between AH and age in the 
group of non-smokers, however, we did not prove this 
dependence in the group of non-smokers. 36% of men 
and 50% of women from the subset of smokers had 
lower values of HDL cholesterol. In case of non-smokers 
it was 42.3% of men and 20% of women. The levels of 
triglycerides (TG) were comparable in both the smoker 
and non-smoker groups. The average body mass index 
(BMI) value of the set was 29.5 kg/m2. In case of all 
men the average value was 29.2 kg/m2 and in case of 
all women it was 29.9 kg/m2. The average BMI value in 
smokers (both men and women) was 29.7 kg/m2 and 
the average value in non-smokers (both men and 
women) was 30.2 kg/m2. We did not show any statisti-
cally significant difference between the BMI values in 
the groups of smokers and non-smokers. Further, we 
examined the type of therapy in the group of patients 
already suffering from diabetes mellitus type 2. In the 
subset of smokers, 46.9% of patients were admin-
istered insulin, whilst in the subset of non-smokers 
it was only 23.5%. These results may be linked with 
increased progression of DM type 2 and the necessity 
of insulin therapy in smokers. Finally, we examined the 
strength of the relation between the number of ciga-
rettes smoked per day and the number of single MS 
components in the group of smokers (p = 0.5799) and 
found no significant relation between the mentioned 
components in our set.
Discussion
Waist circumference
Projects IDEA and NEMESYS proved that there 
is lower prevalence of abdominal obesity in the 
population of smokers, similarly to our findings in 
our examined set of patients. Conversely, a study 
with randomly chosen 13,463 men of the age of 
35 years and more, performed in China, did not 
confirm these data. Overall prevalence of central 
obesity was 35.9%. In contrast to non-smokers, 
only ex-smokers had statistically significantly higher 
prevalence of abdominal obesity [12]. Similarly to 
our observations on the set of patients, no relation 
between the number of cigarettes smoked and the 
waist circumference was found. The IDEA study 
proved that the waist circumference is an independ-
ent risk factor for cardiovascular (CV) diseases. Every 
increase in the waist circumference by 14 cm in men 
and by 14.9 cm in women increases the risk of CV 
disease by 21–40%. Thus, the waist circumference 
became the strongest predictor for CV diseases. The 
relation is even stronger in population of men. This 
relation was also observed in geographical areas 
with low prevalence of abdominal obesity (e.g. East 
Asia) [13–15]. A study by Dutch authors Lean et al. 
proved the waist circumference (greater than 94 cm 
in men and 80 cm in women) to be the strong-
est risk factor for CV diseases in comparison with 
BMI, levels of triglycerides and HDL cholesterol, 
values of blood pressure (BP) and lifestyle.
Diabetes mellitus type 2
It is generally known that smoking increases the 
level of fasting glucose, and we confirmed this associa-
tion in our set off patients. Impaired fasting glucose 
with values higher than 5.6 mmol/L was present in 
39 patients from the group of smokers, which is 66.1% 
of the group. This component of MS was the most 
frequent one in this group. Smoking is an independent 
risk factor for the development of diabetes mellitus 
Figure 1. Frequency of the incidence of single components of 
metabolic syndrome (MS) in patients with MS
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type 2. This is explained by several hypotheses. First 
of all, smoking is a risk factor for hyperinsulinemia. 
Smoking is also linked with chronic pancreatitis and 
pancreatic cancer development [17]. The risk for DM 
type 2 development is significantly higher in patients 
who smoke more than 20 cigarettes per day. Accord-
ing to the study of American Journal of Epidemiology, 
smoking 16–25 cigarettes per day triples the risk of DM 
type 2 compared to non-smokers. However, the highest 
risk of DM type 2 development is in ex-smokers. There 
is up to 70% higher risk of DM type 2 development 
during the first seven years after smoking cessation in 
comparison to non-smokers. The reason for this is prob-
ably a great weight gain [18]. It had been proven that 
passive tobacco exposures may lead to a so-called pan-
creatic “intoxication” and increased risk of DM type 2. 
Other hypotheses state that the passive smoking sup-
ports formation of pre-diabetic states, specifically the 
impaired glucose tolerance [19]. Smoking promotes 
the progression of DM type 2 complications. It also 
causes oxidative stress and transformation of the 
growth factor-b, which leads to changes in the glo-
merular basement membrane. In the population of 
American diabetics, the incidence of microalbuminuria 
and macroalbuminuria was significantly higher in case 
of smokers (53%) compared to non-smokers (20%) 
[3, 20, 21]. Smoking significantly affects the level of 
glycated hemoglobin (HbA1c) [22]. Substances which 
cause increased levels of HbA1c in smoker-diabetics are 
still unknown. It is being discussed that the mentioned 
higher levels of HbA1c may be caused by nicotine 
as such, by direct impact on HbA1c levels and it can 
increase the HbA1c level up to 34%. Obviously, with 
increasing number of cigarettes smoked per day, the 
value of HbA1c is increasing as well. The use of nicotine 
patches, chewing gums etc. is still questionable. The 
advantages of not smoking whilst using these replace-
ments may, however, overweight the risks related to 
these products, but always with emphasis on their 
short-term use [23].
Arterial hypertension
Arterial hypertension is a strong independent risk 
factor for cardiovascular mortality and morbidity. The 
risk of CV diseases triples in case of patients with AH, 
in comparison to those without AH, irrespective of 
age and sex. The risk of cardiovascular morbidity and 
mortality is also noticeably affected by smoking. Every 
10 smoked cigarettes increase the mortality caused by 
CV diseases in men (18%) and in women (31%). Smok-
ing increases the risk of CV diseases at any values of 
blood pressure. Influencing the BP by antihypertensive 
therapy did not bring satisfying results in terms of 
lowering the risk of CV diseases. The risk of CV diseases 
was significantly lowered after other risk factors were 
influenced as well, including smoking. Hypertensive 
patients who smoke 20 cigarettes daily may lower the 
risk of CV diseases up to 35–40% after ceasing smoking. 
Transition to cigarettes with a filter brought no changes 
[2, 24]. According to the project Prevalence of diabetes 
mellitus and metabolic syndrome in Slovakia, arterial 
hypertension is one of the dominant components of MS 
and its incidence increases with age [25]. Throughout 
the whole set of patients, AH was the most frequent 
component of MS, and this proves the dominance of AH 
as the component of MS. Authors observed the preva-
lence of arterial hypertension and other risk factors of 
CV diseases including smoking in a study with 380 Bra-
zilian men of the age of 19–35 years. The prevalence 
of hypertension in the observed group was 22% and 
the incidence of arterial hypertension was 68% higher 
in the ex-smokers compared to the non-smokers. The 
prevalence of arterial hypertension in case of smokers 
was 2 × lower than in case of ex-smokers, which was 
related to the weight gain after smoking cessation. 
With a weight loss of ca. 8 kg the systolic BP was 
lowered by 7–10 mm Hg and diastolic BP was lowered 
by 6–7 mm Hg [26]. Another available analysis proved 
that smoking is not linked with AH (considering both 
systolic and diastolic BP) [27, 28].
Atherogenic dyslipidemia and low values  
of HDL cholesterol
Similarly as in our set of patients, in the project 
Prevalence of diabetes mellitus and metabolic syn-
drome in Slovakia, the values of HDL cholesterol were 
also lower in the population of smokers; moreover, 
it was most frequently found in relatively young pa-
tients (age of 18–29 years). Authors explain this fact 
particularly by the highest prevalence of smoking in 
this age group [29]. In a study with 5,216 patients 
from North American states there were significantly 
lower values of HDL cholesterol in case of smokers 
in comparison to non-smokers (with no difference 
between men or women) and statistically significant 
relation between cigarettes smoked per day and the 
values of HDL cholesterol. The values of HDL choles-
terol in case of men-smokers, who smoked more than 
20 cigarettes per day, were in average 11% lower than 
in non-smokers. In case of women who smoked more 
than 20 cigarettes a day, it was up to 14% in average 
compared to non-smokers [30].
Metabolic syndrome
Prevalence of metabolic syndrome in Slovakia 
according the project Prevalence of diabetes mellitus 
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and metabolic syndrome in Slovakia, which used the 
NCEP/ATP III criteria, is 20.1%. There is significantly 
higher prevalence of MS in women than in men. The 
incidence progressively increases with increasing age 
and also in groups with low social status. The preva-
lence of MS according to this project is comparable 
to other European countries, and, similarly, higher 
prevalence of MS in women is found. The prevalence 
of MS in countries with low risk of CV diseases (e.g. 
Greece) is 24%. Despite comparable prevalence of 
MS in the mentioned countries, and the fact that 
its prevalence in Slovakia is even slightly lower, we 
experience one of the highest mortality rate due to 
CV diseases. This proves that MS is not the only cause 
of this phenomenon [29]. The prevalence of MS in 
Europe is, according to the authors Dellios et al. and 
the IDF criteria, 38% in men and 36% in women. Age 
increases the prevalence of MS in men by the age of 
60 years. After reaching this age, the incidence due to 
age is stabilized. In case of women, the prevalence is 
rising up to the highest age group. The mortality due 
to CV diseases increased by 45% in men with MS and 
up to 73% in women with MS, in comparison to men 
and women without MS in the prospective study of the 
above mentioned authors. The study proved that the 
obese women with DM type 2 are in the highest risk of 
death due to CV diseases [31]. Smoking may be linked 
with higher risk of MS. This theory is supported by sev-
eral scientific studies. According to the D.E.S.I.R. study, 
there is statistically significantly higher incidence of MS 
in male smokers in contrast to male non-smokers. In 
female smokers a higher incidence of MS had not 
been proved [32]. However, opposing evidence exist as 
well. It is appropriate to further examine the relation 
between metabolic syndrome and smoking mainly in 
the population of adult patients in the middle age, for 
whom there is high probability of MS development [33]. 
A study performed in Japan on 3,649 men of the age 
of 36–59 years evaluated the incidence of MS during 
7 years and supplemented data about the ex-smokers, 
who had the highest weight in comparison to the 
smokers and non-smokers. The smokers in this study 
were divided by the number of cigarettes they smoked 
per day. The risk of MS development was significant in 
those, who smoked more than 21 cigarettes per day. 
Body weight was significantly higher in ex-smokers and 
they were in highest risk of MS development. For that 
reason, it is very important to support patients who 
want to cease smoking, mainly in physical activity and 
dietary habits, to prevent them from gaining weight 
[34]. The highest prevalence of MS in ex-smokers was 
also confirmed by a study performed in Saudi Arabia 
on 305 men and 359 women of the age of 25–70 years 
during the period of 2006–2007. The ex-smokers were 
defined as non-smokers for the period of 1–2 years. The 
risk of MS development in ex-smokers in this study was 
2 × higher in comparison to non-smokers (p = 0.009) 
[35]. The incidence of MS has increased in Asian 
countries during the last years. There is also higher 
prevalence of smoking opposed to Western countries, 
and this prevalence is still rising (predominantly in 
the population of young women). Several studies 
on Japanese population showed higher risk for CV 
diseases development in smokers, however, they did 
not prove a relation between MS and smoking. In an-
other Japanese study of the authors Naoyuki Takashima 
et al. the relation between each component of MS 
and risk factors for CV diseases and death had been 
examined. The weightiest risk factors for CV diseases 
and deaths in this study were: smoking, ex-smoking, 
arterial hypertension, and impaired fasting glucose. 
The study also proved that a cumulation of individual 
risk factors increased the risk of death or CV disease 
without respect to obesity presence (assessed according 
to BMI) [36]. In American study on 2,273 individuals 
of the age of 12–19 years the prevalence of MS was 
examined. The examinees were divided into non-smokers 
without exposure to tobacco smoke, passive smokers 
and active smokers. In the population of adolescent 
youth, 5.6% of the participants fulfilled the criteria 
for MS. Throughout the examined set the incidence of 
MS substantially increased with exposure to tobacco. 
The incidence of MS in non-smokers without exposure 
to tobacco smoke was 1.2%, in passive smokers 5.6% 
and in active smokers up to 8.7%. Similar results were 
also recorded in excess weight and obesity assess-
ment, where the weight had increased with exposure 
to tobacco [37].
Body mass index
In common practice, apart from BMI value calcula-
tion, it is essential to find out waist circumference in 
each patient, to determine the fat distribution on the 
body. Abdominal obesity significantly increases the risk 
of insulin resistance and the risk of DM type 2 develop-
ment. An American study on 27,000 men and nearly 
30,000 women assessed the relation between BMI and 
waist circumference. A very strong relation had been 
found between the waist circumference and the mor-
tality due to CV diseases in patients with identical BMI 
values. This means that in patients with identical BMI 
value, the mortality due to CV diseases increases with 
increasing waist circumference. Conversely, in patients 
with identical waist circumference, mortality due to 
CV diseases was not increasing with higher values of 
BMI, moreover, in this group the mortality due to CV 
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diseases increased in cases of lower BMI values. The 
authors link this data with smoking, when patients 
have lower values of BMI, but simultaneously there is 
higher mortality due to CV diseases in this group [38]. 
A project of Swiss authors Chiolero et al. compared 
the BMI values of smokers and non-smokers. Physical 
activity and dietary habits were assessed as well. The 
prevalence of obesity was increasing with age and, 
naturally, higher incidence was related to lower physical 
activity. Men were more physically active, but had worse 
dietary habits than women. Nowadays, the relation 
between BMI and waist circumference is often being 
discussed. A frequently asked question is whether the 
BMI value is equally important risk factor for CV diseases 
as the waist circumference. The waist circumference 
has been repeatedly proven to be stronger risk factor 
for CV diseases than BMI [16].
Conclusion
Most components of the MS are known as the 
risk factors for atherosclerosis and ischemic heart 
disease since the announcement of Framingham study 
results. The original findings of the Framingham study 
were confirmed by numerous subsequent studies and 
they are still valid also with respect to other European 
recommendations [39]. Similarly high is the number 
of evidence based medicine studies on primary and 
secondary prevention that proved the reduction of car-
diovascular consequences of atherosclerosis by risk fac-
tor intervention [40, 41]. Despite the results of our ob-
servation, as well as the other above mentioned studies 
(lower incidence of MS in the population of smokers), 
it is not possible to mark smoking as a protective factor 
regarding the proven adverse effects. Concerning smok-
ing, it is essential to point out the most endangered 
group of patients, and those are the ex-smokers. The 
first 6 months after ceasing smoking are considered to 
be the most risky time period, since the weight gain 
(women are in higher risk than men) and the increased 
risk of weight gain may persist throughout 2 years from 
smoking cessation. Education is very important during 
this period; it is essential to mention lifestyle changes, 
dietary habits and, first of all, the necessity of physical 
exercise for at least 20 minutes each day. 
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